Mast cell tumours (MCTs) are the most common cutaneous malignancies in dogs having often a poor prognosis.

Masivet® is an effective, highly-specific drug, targeting key biological pathways crucial for MCT development and growth.

Masivet® was approved in 2008 by the European Medicine Agency (EMA) in veterinary medicine for the treatment of dog non-resectable MCTs (grade 2 or 3) with presence of a mutated form of the receptor protein c-kit.

In 2018, AB Science celebrated the 10th anniversary of the marketing authorization of Masivet®. Since its approval, Masivet has been used with success as a targeted approach to cancer management in veterinary medicine and tens of thousands of cases have been treated successfully with Masivet®. Veterinary clinics favor the excellent possibilities of case-management of high grade MCTs in the everyday practice with the use of Masivet®.

Masivet® brought veterinary oncology into the modern era by giving it access to targeted therapies.

The Masivet® results in veterinary medicine over the last decade are promising evidence for the clinical development of this compound in human medicine.

The Summary of Product Characteristics is available here.

For any question relative to the use of Masivet, you can contact us at: